Hepatocellular Carcinoma
Conditions
Keywords
hepatocellular carcinoma, macrovascular invasion, portal vein thrombosis
Brief summary
In patients with hgepatocellular carcinoma (HCC) and portal vein tumoral thrombosis (PVTT), Sorafenib represents the treatment of choice but more recently, trans-arterial radioembolization (TARE) with yttrium-90 has been also proposed. A considerable percentage of such patients are not only able to achieve stability of the disease, but also to obtain a complete radiological response (CR). The possibility of achieving a CR might allow these patients to be listed for liver transplantation (LT), in order to cure not only the cancer but also the underlying cirrhosis that generated it.
Interventions
RADIATIONyttrium-90 radioembolization
selective/superselective treatment using resin microspheres labeled with Yttrium-90
Sponsors
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. diagnosis of HCC; 2. age ≥ 18 years; 3. performance status according to Eastern Cooperative Oncology Group 0-1; 4. preserved liver function (Child-Pugh score ≤B7); 5. PVTT limited to the first order portal branch.
Exclusion criteria
1. any contraindication to TARE treatment; 2. macrovascular invasion extended to the main portal trunk and/or to the contralateral portal branch; 3. presence of extra-hepatic disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response to radioembolization | 6 months | The primary endpoint of this study was to assess the effect of radioembolization in HCC patients with PVTT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 5 years | The secondary endpoint was overall survival (OS) |
| Progression-free survival | 5 years | The secondary endpoint was progression-free survival (PFS) |
Outcome results
None listed